This post was originally published on this site
Bayer made the announcement in an update to investors on how it plans to deal with Roundup-related litigation that has dogged the company after it acquired it as part of its $63 billion purchase of Monsanto (NYSE:MON) in 2018.
The decision comes after a U.S. judge in May rejected Bayer’s plan to try and limit the cost of future class action claims that its Roundup weedkiller causes cancer.
